Logo image
Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound
Journal article   Open access   Peer reviewed

Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

Youcef M. Rustum, Karoly Toth, Mukund Seshadri, Arindam Sen, Farukh A. Durrani, Emily Stott, Carl D. Morrison, Shousong Cao and Arup Bhattacharya
Journal of oncology, Vol.2010, pp.396286-13
01/01/2010
DOI: 10.1155/2010/396286
PMCID: PMC2860580
PMID: 20445750
url
https://doi.org/10.1155/2010/396286View
Published (Version of record) Open Access

Abstract

Tumor differentiation enhances morphologic and microvascular heterogeneity fostering hypoxia that retards intratumoral drug delivery, distribution, and compromise therapeutic efficacy. In this study, the influence of tumor biologic heterogeneity on the interaction between cytotoxic chemotherapy and selenium was examined using a panel of human tumor xenografts representing cancers of the head and neck and lung along with tissue microarray analysis of human surgical samples. Tumor differentiation status, microvessel density, interstitial fluid pressure, vascular phenotype, and drug delivery were correlated with the degree of enhancement of chemotherapeutic efficacy by selenium. Marked potentiation of antitumor activity was observed in H69 tumors that exhibited a well-vascularized, poorly differentiated phenotype. In comparison, modulation of chemotherapeutic efficacy by antiangiogenic selenium was generally lower or absent in well-differentiated tumors with multiple avascular hypoxic, differentiated regions. Tumor histomorphologic heterogeneity was found prevalent in the clinical samples studied and represents a primary and critical physiological barrier to chemotherapy.
Life Sciences & Biomedicine Oncology Science & Technology

Details

Metrics

Logo image